Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 109

Showing 26-50 of 109 citing articles:

Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration
Evridiki Asimakidou, Eka Norfaishanty Saipuljumri, Chih Hung Lo, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 4, pp. 1069-1076
Open Access | Times Cited: 10
Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy
Chun Y. Wong, Alberto Baldelli, Camilla M. Hoyos, et al.
Drug Delivery and Translational Research (2024) Vol. 14, Iss. 7, pp. 1776-1793
Open Access | Times Cited: 9
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
Alessandra Dei, M. M. Micheli, Raffaella Aldigeri, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 9, pp. 2339-2349
Open Access | Times Cited: 8
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Jacky Tran, Sneh Parekh, Julia Rockcole, et al.
Life Sciences (2024) Vol. 355, pp. 123001-123001
Closed Access | Times Cited: 8
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
Rishi Desai, Vijay R. Varma, Mufaddal Mahesri, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
The role of insulin resistance and APOE genotype on blood–brain barrier integrity in Alzheimer's disease
Alessandro Padovani, Alice Galli, Elena Bazzoli, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules
Nassima Oumata, Kui Lu, Yuou Teng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114578-114578
Closed Access | Times Cited: 29
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
M. Monney, François R. Jornayvaz, Karim Gariani
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101470-101470
Open Access | Times Cited: 22
Onset age of diabetes and incident dementia: A prospective cohort study
Yongqian Wang, Chenglong Li, Jie Liang, et al.
Journal of Affective Disorders (2023) Vol. 329, pp. 493-499
Closed Access | Times Cited: 17
Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials
Keren Esther Kristina Mantik, Sujin Kim, Bonsang Gu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11450-11450
Open Access | Times Cited: 17
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 17
GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102943-102943
Closed Access | Times Cited: 7
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults
Ivan Koychev, Amanda Adler, Paul Edison, et al.
BMJ Open (2024) Vol. 14, Iss. 6, pp. e081401-e081401
Open Access | Times Cited: 7
Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
Ivan Koychev, Graham Reid, Maggie Nguyen, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 7
Alzheimer’s disease risk reduction in clinical practice: a priority in the emerging field of preventive neurology
Kellyann Niotis, Corey Saperia, Nabeel Saif, et al.
Nature Mental Health (2024) Vol. 2, Iss. 1, pp. 25-40
Closed Access | Times Cited: 6
Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome
Wei Wang, Jinyou Li, Siyuan Cui, et al.
Science Advances (2024) Vol. 10, Iss. 5
Open Access | Times Cited: 6
Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks
Yen‐Wei Pai, I‐Chieh Chen, Jun‐Fu Lin, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 6
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 27
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, et al.
Aging Cell (2023) Vol. 22, Iss. 5
Open Access | Times Cited: 13
A case for seeking sex-specific treatments in Alzheimer’s disease
Marina A. Lynch
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 5
The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment
Sasidhar Gunturu
Indian Journal of Psychological Medicine (2024) Vol. 46, Iss. 3, pp. 193-195
Open Access | Times Cited: 5
Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia
Bin Na Hong, Sungho Bea, Hwa Yeon Ko, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 10, pp. 1319-1329
Closed Access | Times Cited: 5
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102019-102019
Open Access | Times Cited: 5

Scroll to top